Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion

Next Previous
Trial Profile

A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors AbbVie

    • Most Recent Events

    • 17 Jun 2022 Results of final analyses after 5 y from last patients enrolled, including post-hoc subgroup analyses of prognostic markers presented at the 27th Congress of the European Haematology Association
    • 08 Dec 2020 Results (n=1138) of a retrospective analysis assessing rates of tumor lysis syndrome and outcomes and data were pooled from eight clinical studies: M15-550, M15-889, CLL14, M16-778, M14-032, M13-982, M14-728 and MURANO presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
    • 24 Nov 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top